Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19

This randomized, placebo-controlled trial evaluated inhaled fluticasone furoate (200 µg daily for 14 days) in nonhospitalized U.S. adults with mild-to-moderate Covid-19. Among 1277 analyzed participants, there was no significant difference in time to sustained symptom resolution compared to placebo. Hospitalizations were rare and identical across both groups (0.5%). However, urgent care and emergency visits were slightly more frequent in the treatment group. The study concludes that fluticasone furoate did not improve recovery time or clinical outcomes for Covid-19.

This randomized, placebo-controlled trial evaluated inhaled fluticasone furoate (200 µg daily for 14 days) in nonhospitalized U.S. adults with mild-to-moderate Covid-19. Among 1277 analyzed participants, there was no significant difference in time to sustained symptom resolution compared to placebo. Hospitalizations were rare and identical across both groups (0.5%). However, urgent care and emergency visits were slightly more frequent in the treatment group. The study concludes that fluticasone furoate did not improve recovery time or clinical outcomes for Covid-19.